The pathophysiology of penicillamine‐induced myasthenia gravis

Ralph W. Kuncl, Alan Pestronk, Daniel B. Drachman, Emanuel Rechthand

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

The temporal course and pathophysiology of penicillamine‐induced myasthenia gravis were studied in detail in a typical case. Our results suggest that this disorder and idiopathic autoimmune myasthenia gravis share the same essential pathophysiological features, including the presence of anti–acetylcholine receptor (AChR) antibody, serum‐induced blockade of AChRs, antibody‐mediated accelerated degradation of AChRs, and a resultant quantitative reduction in available junctional AChRs. An initial severe reduction in junctional AChRs was reversed and the patient recovered, both within 8 months of stopping penicillamine. Our data suggest that penicillamine probably produced myasthenia gravis by initiating a new autoimmune response rather than by enhancing ongoing autoimmunity.

Original languageEnglish (US)
Pages (from-to)740-744
Number of pages5
JournalAnnals of neurology
Volume20
Issue number6
DOIs
StatePublished - Dec 1986
Externally publishedYes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'The pathophysiology of penicillamine‐induced myasthenia gravis'. Together they form a unique fingerprint.

Cite this